30 completed, 3 recruiting, 3 terminated, 1 not yet recruiting. 39 Phase 1, 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 39 | Completed 30, Recruiting 3, Terminated 3, Not yet recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 10 | Completed 9, Recruiting 1 |
Follow Colonic Diseases, Functional: new trials by email Literature Review of Colonic Diseases, Functional trials Research Report on Colonic Diseases, Functional
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SIMBA in Irritable Bowel Syndrome (IBS) Rifaximin (drug), fluid biopsy capsule - Irritable Bowel Syndrome (IBS), Microbiome | Phase 1 | Not yet recruiting | University of Calgary | 180 | 2026-11-01 | 2026-10-20 |
| Safety and Efficacy of Lyophilized Faecal Microbiota Transplantation Via Capsules in Treatment of Irritable Bowel Syndrome FMT capsule, Placebo - Irritable Bowel Syndrome (IBS) | Phase 1 / Phase 2 | Recruiting | University of Rijeka | 70 | 2026-03-15 | 2026-03-18 |
| Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers. Trimedat® - Irritable Bowel Syndrome, Gallstone Disease | Phase 1 | Recruiting | Valenta Pharm JSC | 36 | 2025-11-06 | 2026-02-19 |
| A Study of Varenicline in the Treatment of Visceral Sensation Varenicline - Irritable Bowel Syndrome | Phase 1 | Completed | Mayo Clinic | 8 | 2025-06-01 | 2026-01-06 |
| Efficacy of Repeated Transcranial Magnetic Stimulation Combined With a Live Probiotic Tablet (Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live) in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) rTMS combined with Live Probiotic tablet, rTMS combined placebo, shamrTMS combined with Live Probiotic tablet - Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea (IBS-D) | Phase 1 | Recruiting | The First Affiliated Hospital of Soochow University | 400 | 2024-12-01 | 2025-05-07 |
| Saccharomyces Cerevisiae for Irritable Bowel Syndrome Saccharomyces cerevisiae - Irritable Bowel Syndrome | Phase 1 / Phase 2 | Completed | Ziauddin University | 30 | 2021-03-01 | 2022-12-07 |
| Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome Olorinab, Placebo - Irritable Bowel Syndrome | Phase 1 | Terminated | Arena Pharmaceuticals | 1 | 2021-01-29 | 2021-05-17 |
| Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study TD-1473, Itraconazole - Inflammatory Bowel Disease | Phase 1 | Completed | Theravance Biopharma | 36 | 2018-06-13 | 2021-01-14 |
| Therapeutic Oxygen for Gastrointestinal Atony (TOGA) 100% Oxygen - Ileus, Ogilvie Syndrome | Phase 1 | Completed | University of Florida | 17 | 2018-01-25 | 2019-12-12 |
| Use of a Prokinetic Agent as an Adjunct to Thrice Weekly Bowel Care After SCI Neostigmine and Glycopyrrolate, Iontophoresis - Spinal Cord Injuries, Constipation | Phase 1 | Completed | James J. Peters Veterans Affairs Medical Center | 6 | 2018-01-15 | 2021-12-30 |
| The Impact of a Combination of Bifidobacterium Longum 35624® and 1714™ Strains in Adults With Irritable Bowel Syndrome Probiotic capsule - IBS - Irritable Bowel Syndrome, Depression, Anxiety | Phase 1 / Phase 2 | Completed | PrecisionBiotics Group Ltd. | 40 | 2017-09-20 | 2020-06-09 |
| A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers GSK3352589, Matching Placebo - Irritable Bowel Syndrome | Phase 1 | Completed | GlaxoSmithKline | 68 | 2017-05-17 | 2019-08-09 |
| A Phase I, Randomized, Placebo-controlled, Double Blind, Repeat Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Gastrointestinal Transit Time and Pharmacodynamic Biomarkers of GSK3179106 in Normal Subjects GSK3179106, Matched Placebo - Irritable Bowel Syndrome | Phase 1 | Completed | GlaxoSmithKline | 46 | 2016-06-01 | 2017-01-18 |
| A Study to Evaluate Fecal Microbiota Transplantation Engraftment in IBS fecal microbiota transplantation, placebo fecal microbiota transplantation, FMT with antibiotic pre-treatment (v1) - Irritable Bowel Syndrome | Phase 1 | Completed | Beth Israel Deaconess Medical Center | 80 | 2016-05-01 | 2019-12-23 |
| A Phase 1, Randomized, Placebo-Controlled, Ascending Cohort, Dose Escalation Study in Normal Healthy Volunteers GSK3179106, Placebo - Irritable Bowel Syndrome | Phase 1 | Completed | GlaxoSmithKline | 16 | 2015-11-26 | 2017-05-08 |
| Effect of Vitamin D3 Supplementation in Treatment of Irritable Bowel Syndrome Vitamin D3 (Cholecalciferol), placebo - Irritable Bowel Syndrome | Phase 1 | Completed | Ahvaz Jundishapur University of Medical Sciences | 90 | 2015-02-01 | 2015-11-30 |
| A Lactation Study in Women Who Are Breastfeeding or Pumping and Are Receiving Linaclotide Therapeutically linaclotide - Breast Feeding, Constipation | Phase 1 | Completed | Forest Laboratories | 7 | 2014-07-31 | 2020-12-19 |
| The Effects of Laxative-probiotic Sequential Treatment in the Irritable Bowel Syndrome Patients Probiotic Clostridium Butyricum, Laxative Polyethylene Glycol - Irritable Bowel Syndrome | Phase 1 | Completed | Shandong University | 56 | 2014-07-01 | 2016-08-31 |
| Effect of TU-100 in Patients With Irritable Bowel Syndrome (IBS) Daikenchuto (TU-100), Placebo - Irritable Bowel Syndrome, Digestive System Diseases | Phase 1 / Phase 2 | Completed | Tsumura USA | 40 | 2013-08-01 | 2016-06-13 |
| Efficacy of a Multi-strain Probiotic in the Treatment of Irritable Bowel Syndrome Kyodophilus multi-strain probiotic capsules, Kyodophilus Matching Placebo Capsules - Irritable Bowel Syndrome, Digestive System Diseases | Phase 1 / Phase 2 | Completed | The Canadian College of Naturopathic Medicine | 100 | 2013-06-01 | 2015-03-17 |
Showing 20 of 39. Sign in to see all of them.
Irritable Bowel Syndrome (35) · Constipation (7) · Diarrhea (4) · Abdominal Pain (3) · Digestive System Diseases (3) · Gastrointestinal Diseases (2) · Mucopolysaccharidosis IV (2) · Multiple Endocrine Neoplasia Type 2a (2) · Neurogenic Bowel (2) · Pain (2) · Spasm (2) · Spinal Cord Injuries (2) · Anxiety Disorders (1) · Biliary Dyskinesia (1)
Colonic Diseases (39) · Intestinal Diseases (38) · Gastrointestinal Diseases (37) · Digestive System Diseases (36) · Pathological Conditions, Signs and Symptoms (13) · Signs and Symptoms (10) · Signs and Symptoms, Digestive (9) · Neurologic Manifestations (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Genetic Diseases, Inborn (5) · Nervous System Diseases (5) · Pathologic Processes (3) · Skin and Connective Tissue Diseases (3) · Behavior (2)
Fecal Microbiota Transplantation (2) · Glucagon-Like Peptide 1 (2) · Glycopyrrolate (2) · Lubiprostone (2) · Probiotics (2) · 12,13-dihydro-N-methyl-6,11,13-trioxo-5H-benzo(4,5)cyclohepta(1,2-b)naphthalen-5,12-imine (1) · Acupuncture Therapy (1) · Cholecalciferol (1) · GSK3352589 (1) · GW 876008 (1) · Iontophoresis (1) · Itraconazole (1) · Melatonin (1) · N-((1-(3-(1,2,3-triazol-1-yl)propyl)piperidin-4-yl)methyl)-4-amino-5-chloro-2-methoxybenzamide (1) · Neostigmine (1)
GlaxoSmithKline (5) · Mayo Clinic (3) · James J. Peters Veterans Affairs Medical Center (2) · The Canadian College of Naturopathic Medicine (2) · Uppsala University (2) · Ahvaz Jundishapur University of Medical Sciences (1) · Arena Pharmaceuticals (1) · Avera Pharmaceuticals (1) · Baylor College of Medicine (1) · Beth Israel Deaconess Medical Center (1) · Dayton Children's Hospital (1) · Dong-A ST Co., Ltd. (1) · Forest Laboratories (1) · Hadassah Medical Organization (1) · Lexicon Pharmaceuticals (1)
United States (21) · Canada (5) · Australia (3) · Sweden (3) · China (2) · Croatia (1) · Iran (1) · Ireland (1) · Israel (1) · Pakistan (1) · Russia (1) · South Korea (1) · United Kingdom (1)
Dugald Seely, ND (2) · Michael Camilleri, MD (2) · Adrian Miranda, MD (1) · Anthony Lembo, MD (1) · Arena CT.gov Administrator (1) · Brian C. Weiner, MD (1) · Christopher N Andrews, MD MSc (1) · Eileen Murphy, PhD (1) · Ikenna Ogbaa, MD (1) · Joao Siffert, MD (1) · John K. DiBaise, M.D. (1) · Kirsten Tillisch, MD (1)
PMID 30277655, PMID 18298441, PMID 18390493, PMID 22517769, PMID 25617726, PMID 28483500, PMID 29177486, PMID 33168839, PMID 33606922, PMID 34854473, PMID 35014601, PMID 35295488, PMID 39131150
R01NR005337 (1), R21AT003400 (1), UL1RR024150 (1)